Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Eosinophilic Gastrointestinal Disorders (EGIDs): early-phase trial registry

1 of 2 indexed Eosinophilic Gastrointestinal Disorders (EGIDs) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Eosinophilic Gastrointestinal Disorders (EGIDs): 2 US clinical trials tracked, 1 recruiting.

Eosinophilic Gastrointestinal Disorders (EGIDs) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital Medical Center, Cincinnati, running 2 of these trials.

Enrollment posture brief

Registry condition eosinophilic-gastrointestinal-disorders-egids

OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Eosinophilic Gastrointes (th…50%
Open-enrollment share among volume-matched conditions near Eosinophilic Gastrointestinal Disorders (EGIDs)

Eosinophilic Gastrointestinal Disorders (EGIDs) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Eosinophilic Gastrointestinal Disorders (EGIDs) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Eosinophilic Gastrointestinal Disorders (EGIDs) is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Eosinophilic Gastrointestinal Disorders (EGIDs) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fluticasone Propionate, 880 mcg twice daily (after 6FED failure) Drug
1 trials
6 Food Elimination Diet (after 1FED failure) Other
1 trials
6 Food Elimination Diet Therapy Other
1 trials
1 Food Elimination Diet Therapy Other
1 trials

US sites by state

Facility locations filed on Eosinophilic Gastrointestinal Disorders (EGIDs) trials. A trial with sites in several states counts in each.

Utah 2 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
North Carolina 2 trials
Minnesota 2 trials
Massachusetts 2 trials
Illinois 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Eosinophilic Gastrointestinal Disorders (EGIDs) page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eosinophilic Gastrointestinal Disorders (EGIDs) condition card totals 2 registered trials; most-linked intervention Fluticasone Propionate, 880 mcg twice daily (after 6FED failure); top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.